Since the most sophisticated market participants have access to resources that regular folks lack, their posture can clue us into potential sentiment swings.
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, TEV-‘408 ...
Teva Pharmaceutical (TEVA) is trading at new 5-year highs. Shares are up more than 40% over the past year. The stock has strong technical momentum, maintaining a 100% “Buy” opinion from Barchart. TEVA...
/Viatris%20Inc%20logo%20on%20building-by%20SSKH-Pictures%20via%20Shutterstock.jpg)
As Viatris has outperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Teva Pharmaceutical (TEVA – Research Report), Enovis (ENOV – Research Report) and Healthequity (HQY...
Johnson & Johnson’s JNJ stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since mid-June. It achieved the golden cross in mid-July, after the company announced strong...
Johnson & Johnson JNJ faces several challenges, like potential losses from expiring drug patents, ongoing legal battles related to its talc powder and broader macroeconomic uncertainties. Here, we discuss...
Johnson & Johnson JNJ delivered strong second-quarter 2025 results, with both the top and bottom lines exceeding expectations.Despite the loss of exclusivity (“LOE”) of its multi-billion-dollar product,...
Johnson & Johnson’s JNJ second-quarter 2025 earnings came in at $2.77 per share, which beat the Zacks Consensus Estimate of $2.66. Earnings, however, declined 1.8% from the year-ago period.Adjusted...
Teva Pharmaceutical Industries Limited’s TEVA shares have risen 21.6% in three months. Over the past few quarters, Teva has successfully launched several biosimilars and other high-value, complex generics,...